Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
Share this Article:
Tweet
|
Company
Speclipse
Headquarters
Sunnyvale, CA
Management
Sung Hyun Pyun, CEO
Description
Speclipse is widely known as a developer of a patented non-invasive, in-vivo skin cancer diagnostic solution, Spectra-Scope. The device diagnoses skin cancer with the utmost efficiency and accuracy by detecting skin tissue biochemical information through laser-induced plasma spectroscopy (LIPS). This enables patients to get rid of an unnecessary biopsy. Establishing the company with a single product and growing over the years, Speclipse is catering to a wide range of skincare clinics that currently conducts skin check-up or/and skin biopsy. Striding forward, the company envisions a partnership with the dealers to engage in local sales activities. Also, several laser companies and medical device companies are interested in partnering with Speclipse to repurpose their core technology for more specialized applications
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info